Ocean Biomedical enters first in-human clinical trial Oct 13, 2023 Providence Business Journal Read More Ocean Biomedical and Virion Therapeutics form JV for chronic hepatitis study Oct 12, 2023 Providence Business Journals Read More Ocean Biomedical forms JV with Virion Therapeutics to find treatments for cancer and chronic infectious diseases Oct 12, 2023 AlphaStreet Read More Ocean Biomedical and Virion Therapeutics form JV for chronic hepatitis study Oct 12, 2023 Seeking Alpha Read More Ocean Biomedical’s cancer-targeting antibody candidate shows effective tumor reduction against a subset of NSCLC with EGFR mutations Oct 03, 2023 AlphaStreet Read More Ocean Biomedical Announces New Patent For Fibrosis Candidate Catering To One Of Leading Death Causes In US Aug 29, 2023 Benzinga Read More Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S. Aug 29, 2023 Yahoo finance Read More Ocean Biomedical: Some New Targets, No Clinical Data. Not For Me Aug 28, 2023 Seeking alpha Read More Ocean Biomedical shares details of its successful lung cancer program on World Lung Cancer Day Aug 01, 2023 AlphaStreet Read More Market Surges and Notable Achievements August 1 2023 Aug 01, 2023 Best Stocks Read More
Ocean Biomedical enters first in-human clinical trial Oct 13, 2023 Providence Business Journal Read More
Ocean Biomedical and Virion Therapeutics form JV for chronic hepatitis study Oct 12, 2023 Providence Business Journals Read More
Ocean Biomedical forms JV with Virion Therapeutics to find treatments for cancer and chronic infectious diseases Oct 12, 2023 AlphaStreet Read More
Ocean Biomedical and Virion Therapeutics form JV for chronic hepatitis study Oct 12, 2023 Seeking Alpha Read More
Ocean Biomedical’s cancer-targeting antibody candidate shows effective tumor reduction against a subset of NSCLC with EGFR mutations Oct 03, 2023 AlphaStreet Read More
Ocean Biomedical Announces New Patent For Fibrosis Candidate Catering To One Of Leading Death Causes In US Aug 29, 2023 Benzinga Read More
Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S. Aug 29, 2023 Yahoo finance Read More
Ocean Biomedical: Some New Targets, No Clinical Data. Not For Me Aug 28, 2023 Seeking alpha Read More
Ocean Biomedical shares details of its successful lung cancer program on World Lung Cancer Day Aug 01, 2023 AlphaStreet Read More